www.fdanews.com/articles/73727-revotar-biopharmaceuticals-granted-orphan-drug-designation
REVOTAR BIOPHARMACEUTICALS GRANTED ORPHAN-DRUG DESIGNATION
June 27, 2005
Revotar Biopharmaceuticals AG (Revotar) announced today that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMEA) has granted orphan-drug designation to Revotar's pan-selectin antagonist bimosiamose disodium for the treatment of acute lung injury.
BioSpace
(http://www.biospace.com/news_story.cfm?StoryID=20386220&full=1)